Edwards Lifesciences’ Unifying Generations Report Seeks to Transform Perceptions of the “Pivotal” 3rd Generation
21.6.2022 11:00:00 EEST | Business Wire | Press release
Edwards Lifesciences today published ‘Unifying Generations: Building the Pathway to Intergenerational Solidarity’ – a report, based on a survey of 12,850 Europeans across generations, that demonstrates the need to change perceptions of the value of people aged over-65 and their cohesion with younger generations.
“The European population is ageing. By 2040, 155 million people are expected to be over 65 1 . This demographic change is often referred to as a challenge, which gives a misleading and negative impression of the contributions of over-65s to the society,” commented Jean-Luc Lemercier, Corporate Vice President, EMEA, Canada and Latin America, Edwards Lifesciences. “The survey results demonstrate that the senior population, and especially the pivotal 3rd generation, is an active, committed and engaged contributor to cohesion within families and the community.”
To provide insights on the role of the senior population in society and the benefits of intergenerational interactions, Edwards Lifesciences joined forces with experts to conduct a survey examining the perceptions and experience of intergenerational solidarity of 12,850 citizens across 6 European countries (France, Germany, Ireland, Italy, Spain, and the UK). The results formed the basis of the newly available Unifying Generations report.
In contrast to existing perceptions, the survey results highlighted the significant social contributions of the 3rd generation. They contribute to their families and communities, through volunteering (19%) and providing care to others (24%).2 Seventy-one percent (71%) of over-65s also provide significant financial support to younger people.2 Younger generation respondents stated how important they felt the support the older generation provided was in their day-to-day lives, with 83% stating it was very important or somewhat important.2
“The Unifying Generations Survey gives an accurate picture of the current situation of intergenerational solidarity in several European countries. The results of this survey show a strong desire for more intergenerational interactions from both younger and older generations. The survey also presents the great value of listening, mentoring and coaching; contributing to community well-being through volunteering; sharing knowledge of new technology and digital skills; and many other ways of encouraging cooperation in a society for all ages. The survey data is a useful reference document that will encourage social organisations to promote intergenerational solidarity programs at local, national and international levels in European countries,” commented Mr. Angel Yagüe Criado, Project Manager, The Spanish Confederation of Older People’s Association (CEOMA).
Results showed that the pandemic seems to have had a negative impact on intergenerational interaction, with 40% of respondents saying they spend less time with different generations since the pandemic.2 However, one of the most positive themes that emerged from the report was the willingness to improve intergenerational interactions. Respondents were 11 times more likely to think closer relations between different generations are a good thing (77%) vs. a bad thing (7%). 2 In fact, 92% of survey respondents confirmed they were open to having a friend from a different generation.
“The study suggests that extremely positive and varied intergenerational interactions are present in society and also valued by all age groups. It’s important that policies and strategies are developed that help maintain and strengthen these relations going forward,” said Prof George W Leeson, Professorial Fellow, Oxford Institute of Population Ageing, University of Oxford.
A number of different benefits of improving intergenerational interactions were also highlighted. The most important benefits identified were companionship or friendship (20%) and mental and emotional wellbeing (19%). Additionally, 23% of younger respondents believe that mentoring or educational schemes provided by national or local government would help them to do more with older generations.2
The report recommends three actions that can be considered as a result of the survey findings. They are: a campaign to transform perceptions of the value of senior people and their interactions with younger generations, greater opportunities for mentoring and knowledge sharing from older to younger generations; and schemes that help senior people interact more digitally.
“Recognising and celebrating the knowledge, skills, and experiences of senior people is at the heart of the report and of promoting intergenerational solidarity,” added Jean-Luc Lemercier. “As we build back after the pandemic, we should change perceptions of the value our senior populations – particularly the pivotal 3rd generation – provide to society and the importance of protecting their health and well-being.”
To learn more and download the full report please visit https://www.edwards.com/ch-en/aboutus/unifying-generations/.
About Edwards Lifesciences
Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on LinkedIn and Twitter.
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
About Unifying Generations
Unifying Generations is an initiative that springs from the company’s commitment to the patients it serves and illustrates the aspiration to create a community unified in its mission to improve the quality of life around the world.
###
1 Eurostat (2017) People in the EU – population projections, http://ec.europa.eu/eurostat/statistics-explained/index.php?-title=People_in_the_EU_-_population_projections
2 Censuswide. Unifying Generations. A survey of over 12,850 people in Europe. Survey carried out 04/04/2022 – 14/04/2022. Data on file. Survey funded by Edwards Lifesciences.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005242/en/
Contact information
Media contacts:
Julie Tracol
julie_tracol@edwards.com
+41 (0)75 431 74 95
Michael George
Michael_George@edwards.com
+41 79 487 71 47
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
